T cells in the pathogenesis of type 1 diabetes

Current Diabetes Reports

Volumn 8, Issue 2, 2008, Pages 101-106

  Mallone, Roberto ^b   van Endert, Peter ^a  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AUTOANTIBODY; AUTOANTIGEN; B LYMPHOCYTE ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CELL PROTEIN; EPITOPE; GAMMA INTERFERON; GLUCOSE 6 PHOSPHATASE; GLUTAMATE DECARBOXYLASE 65; HLA A1 ANTIGEN; HLA A2 ANTIGEN; INSULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROINSULIN; TYROSINE;

AMINO ACID SUBSTITUTION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DESTRUCTION; CELLULAR IMMUNITY; CYTOKINE RELEASE; DIAGNOSTIC VALUE; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL RESEARCH; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PATHOGENESIS; PROGNOSIS; REVIEW; T LYMPHOCYTE; TRANSGENIC MOUSE; ANIMAL; HUMAN; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; AUTOANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; EPITOPES; HLA-A2 ANTIGEN; HUMANS; INSULIN-SECRETING CELLS; T-LYMPHOCYTES;

EID: 44849112223     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0019-9     Document Type: Review

References (49)

1. Bottazzo GF, Florin-Christensen A, Doniach D: Islet-cell antibodies in diabetes mettitus with autoimmune polyendocrine deficiencies. Lancet 1974, 2:1279-1283.
2. Reijonen H, Daniels TL, Lernmark A, Nepom GT: GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. Diabetes 2000, 49:1621-1626.
3. Martin S, Wolf-Eichbaum D, Duinkerken G, et al.: Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001, 345:1036-1040.
4. Haskins K, Wegmann D: Diabetogenic T-cell clones. Diabetes 1996, 45:1299-1305.
5. Katz J, Benoist C, Mathis D: Major histocompatibility complex class I molecules are required for the development of insulitis in non-obese diabetic mice. Eur J Immunol 1993, 23:3358-3360.
6. Serreze DV, Leiter EH, Christianson GJ, et al.: Major histocompatibility complex class I-deficient NOD-B2mnull mice are diabetes and insulitis resistant. Diabetes 1994, 43:505-509.
7. Wicker LS, Leiter EH, Todd JA, et al.: Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes 1994, 43:500-504.
8. Wang B, Gonzalez A, Benoist C, Mathis D: The role of CD8+ T cells in the initiation of insulin-dependent diabetes mellitus. Eur J Immunol 1996, 26:1762-1769.
9. Wong FS, Karttunen J, Dumont C, et al.: Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med 1999, 5:1026-1031.
10. Amrani A, Verdaguer J, Serra P, et al.: Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 2000, 406:739-742.
11. DiLorenzo TP, Serreze DV: The good turned ugly: immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice. Immunol Rev 2005, 204:250-263.
12. Walter U, Santamaria P: CD8+ T cells in autoimmunity. Curr Opin Immunol 2005, 17:624-631.
13. Bendelac A, Carnaud C, Boitard C, Bach JF: Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt2+ T cells. J Exp Med 1987, 166:823-832.
14. Nagata M, Santamaria P, Kawamura T, et al.: Evidence for the role of CD8+ cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese diabetic mice. J Immunol 1994, 152:2042-2050.
15. Serreze DV, Chapman HD, Varnum DS, et al.: Initiation of autoimmune diabetes in NOD/Lt mice is MHC class I-dependent. J Immunol 1997, 158:3978-3986.
16. Graser RT, DiLorenzo TP, Wang F, et al.: Identification of a CD8 T cell that can independently mediate autoimmune diabetes development in the complete absence of CD4 T cell helper functions. J Immunol 2000, 164:3913-3918.
17. Daniel D, Gill RG, Schloot N, Wegmann D: Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur J Immunol 1995, 25:1056-1062.
18. Thebault-Baumont K, Dubois-Laforgue D, Krief P, et al.: Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J Clin Invest 2003, 111:851-857.
19. French MB, Allison J, Cram DS, et al.: Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes 1997, 46:34-39.
20. Moriyama H, Abiru N, Paronen J, et al.: Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci U S A 2003, 100:10376-10381.
21. Nakayama M, Abiru N, Moriyama H, et al.: Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005, 435:220-223.
22. Nakayama M, Beilke JN, Jasinski JM, et al.: Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity. J Clin Invest 2007, 117:1835-1843.
23. Krishnamurthy B, Dudek NL, McKenzie MD, et al.: Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest 2006, 116:3258-3265.
24. Lieberman SM, Takaki T, Han B, et al.: Individual nonobese diabetic mice exhibit unique patterns of CD8+ T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophia myotonica kinase. J Immunol 2004, 173:6727-6734.
25. Kubosaki A, Gross S, Miura J, et al.: Targeted disruption of the IA-2beta gene causes glucose intolerance and impairs insulin secretion but does not prevent the development of diabetes in NOD mice. Diabetes 2004, 53:1684-1691.
26. Jaeckel E, Klein L, Martin-Orozco N, von Boehmer H: Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase. J Exp Med 2003, 197:1635-1644.
27. Jaeckel E, Lipes MA, von Boehmer H: Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes. Nat Immunol 2004, 5:1028-1035.
28. Han B, Serra P, Amrani A, et al.: Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide. Nat Med 2005, 11:645-652.
29. Bielekova B, Goodwin B, Richert N, et al.: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000, 6:1167-1175.
30. Kappos L, Comi G, Panitch H, et al.: Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000, 6:1176-1182.
31. Thomas HE, Darwiche R, Corbett JA, Kay TW: Evidence that beta cell death in the nonobese diabetic mouse is Fas independent. J Immunol 1999, 163:1562-1569.
32. Yamada K, Takane-Gyotoku N, Yuan X, et al.: Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia 1996, 39:1306-1312.
33. Amrani A, Verdaguer J, Thiessen S, et al.: EL-1alpha, IL-1beta, and IFN-gamma mark beta cells for Fas-dependent destruction by diabetogenic CD4(+) T lymphocytes. J Clin Invest 2000, 105:459-468.
34. Perez-Diez A, Joncker NT, Choi K, et al.: CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007, 109:5346-5354.
35. Allison J, Thomas HE, Catterall T, et al.: Transgenic expression of dominant-negative Fas-associated death domain protein in beta cells protects against Fas ligand-induced apoptosis and reduces spontaneous diabetes in nonobese diabetic mice. J Immunol 2005, 175:293-301.
36. Kagi D, Odermatt B, Seiler P, et al.: Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med 1997, 186:989-997.
37. Bottazzo GF, Dean BM, McNally JM, et al.: In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 1985, 313:353-360.
38. Arif S, Tree TI, Astill TP, et al.: Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004, 113:451-463.
39. Mallone R, Martinuzzi E, Blancou P, et al.: CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes. Diabetes 2007, 56:613-621.
40. Seyfert-Margolis V, Gisler TD, Asare AL, et al.: Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes 2006, 55:2588-2594.
41. Pugliese A, Zeller M, Fernandez A, Jr, et al.: The insulin gene is transcribed in the human thymus and transcription levels correlated with allefic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997, 15:293-297.
42. Diabetes Prevention Trial-Type 1 Diabetes Study G: Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002, 346:1685-1691.
43. Hassainya Y, Garcia-Pons F, Kratzer R, et al.: Identification of naturally processed HLA-A2-restricted proinsulin epitopes by reverse immunology. Diabetes 2005, 54:2053-2059.
44. Blancou P, Mallone R, Martinuzzi E, et al.: Immunization of HLA class I transgenic mice identifies autoantigenic epitopes eliciting dominant responses in type 1 diabetes patients. J Immunol 2007, 178:7458-7466.
45. Ouyang Q, Standifer NE, Qin H, et al.: Recognition of HLA class I-restricted beta-cell epitopes in type 1 diabetes. Diabetes 2006, 55:3068-3074.
46. Pinkse GG, Tysma OH, Bergen CA, et al.: Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A 2005, 102:18425-18430
47. Standifer NE, Ouyang Q, Panagiotopoulos C, et al.: Identification of Novel HLA-A°0201-restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relatives. Diabetes 2006, 55:3061-3067.
48. Toma A, Haddouk S, Briand JP, et al.: Recognition of a subregion of human proinsulin by class I-restricted T cells in type 1 diabetic patients. Proc Natl Acad Sci U S A 2005, 102:10581-10586.
49. Monti P, Scirpoli M, Rigamond A, et al.: Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes. J Immunol 2007, 179:5785-5792.